DGE invites Clinical Innovation and Development experts, Patient Recruitment specialists, and Clinical Safety/Regulatory Affairs officers, to attend the 7th Decentralized & Hybrid Clinical Trials Summit, to be held in Philadelphia, PA, May 10-11, 2023.
Decentralized and hybrid clinical trials remove geographic hurdles and increase patient participation rates and diversity – as long as the teams are aptly trained and have the right technology and partners.
The 7th Decentralized & Hybrid Clinical Trials Summit is the industry’s most reliable conference for providing key strategies on a subject that, in the post-COVID era, became essential. Attendees will gain new approaches for improving patient-centricity and study enrollment, irrespective of therapeutic area or population size.
A decentralized clinical trial DCT is about more than just presenting new digital tools and technologies. Transformation requires the serious reconsidering of old ways of working, and the willingness to implement new behaviors. The Philadelphia summit offers the following to directly address these issues:
- Refining patient recruitment strategy
- Quickly upscaling digital technologies
- Prioritizing patient diversity
- Adapting biospecimen collection and management methods
- Benefiting from retail pharmacy partners
Prioritizing Patient Centricity in Remote Clinical Development
With the global virtual clinical trial market value projected to expand at a compound annual growth rate (“CAGR”) of 5.1% from 2020 to 2027 from a baseline of $7.0 billion in 2019, the era of DCT is here to stay.
The clinical trial landscape is dynamic. New innovations and technology have changed clinical trial design. COVID placed greater industry emphasis on remote and decentralized clinical trials, which can be specifically valuable for late-stage studies. DCTs represent an exemplary shift that can deliver a greater level of diversity in trials than previously seen.
The acceptance rate of decentralized trials is likely to rise to more than 50% by 2024. As this innovative method of steering studies continue to decrease the patient burden and eliminate barriers to access, the drive to adopt DCT at a full enterprise scale is increasing.
The most complicated and time-consuming phase of the clinical trial process is patient recruitment and retention. Customary recruitment approaches have significantly failed to garner a wider and more diverse group of study participants to represent real-world patients. With DCTs holding the potential for more study enrollment, businesses need to reconsider their recruitment strategies. This approach leverages mobile or community-based providers (imaging facilities, ambulatory clinics, and laboratory centers), digital tools, and a supply chain to exclude the need for routine in-person interactions.
To learn more, please visit https://ibn.fm/IBbV1
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]